Literature DB >> 18321823

First-line treatment of advanced gastric cancer and hepatic dysfunction with oxaliplatin, 5-fluorouracil and cetuximab.

Andrés Jesús Muñoz Martín1, Virginia Martínez Marín, Juan Luis Arranz Cózar, Luis Cabezón Gutiérrez, Ricardo González del Val Subirats, Pilar García Alfonso.   

Abstract

There is no standard chemotherapy regimen in advanced gastric cancer with poor performance status and hepatic dysfunction. New chemotherapeutical agents and targeted therapy have demonstrated promising results in terms of efficacy and safety in phase II clinical trials. We report the case of a 68-year-old man with stage IV gastric cancer and severe hepatic dysfunction due to liver metastases treated with a combination of oxaliplatin, 5-fluorouracil and cetuximab.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18321823     DOI： 10.1007/s12094-008-0178-9

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN： 1699-048X            Impact factor:   3.405


  7 in total

1.  Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma.

Authors:  Manish A Shah; Ramesh K Ramanathan; David H Ilson; Alissa Levnor; David D'Adamo; Eileen O'Reilly; Archie Tse; Robin Trocola; Lawrence Schwartz; Marinela Capanu; Gary K Schwartz; David P Kelsen
Journal:  J Clin Oncol       Date:  2006-11-20       Impact factor: 44.544

Review 2.  Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data.

Authors:  Anna D Wagner; Wilfried Grothe; Johannes Haerting; Gerhard Kleber; Axel Grothey; Wolfgang E Fleig
Journal:  J Clin Oncol       Date:  2006-06-20       Impact factor: 44.544

Review 3.  Oxaliplatin-related side effects: characteristics and management.

Authors:  Jim Cassidy; Jean-Louis Misset
Journal:  Semin Oncol       Date:  2002-10       Impact factor: 4.929

4.  Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study).

Authors:  C Pinto; F Di Fabio; S Siena; S Cascinu; F L Rojas Llimpe; C Ceccarelli; V Mutri; L Giannetta; S Giaquinta; C Funaioli; R Berardi; C Longobardi; E Piana; A A Martoni
Journal:  Ann Oncol       Date:  2006-12-12       Impact factor: 32.976

Review 5.  Epidemiology of cancer: global patterns and trends.

Authors:  D M Parkin
Journal:  Toxicol Lett       Date:  1998-12-28       Impact factor: 4.372

6.  Impact of epidermal growth factor (EGF) radioreceptor analysis on long-term survival of gastric cancer patients.

Authors:  R Kopp; M Ruge; E Rothbauer; C Cramer; H J Kraemling; B Wiebeck; F W Schildberg; A Pfeiffer
Journal:  Anticancer Res       Date:  2002 Mar-Apr       Impact factor: 2.480

Review 7.  Evaluation of the response to treatment of solid tumours - a consensus statement of the International Cancer Imaging Society.

Authors:  J E Husband; L H Schwartz; J Spencer; L Ollivier; D M King; R Johnson; R Reznek
Journal:  Br J Cancer       Date:  2004-06-14       Impact factor: 7.640
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.